Lipum advances SOL-116 toward phase IIa trials
The company completed its merger with Flerie, published Phase I results, and secured €8 million in funding to prepare for proof-of-concept studies.
See the latest news and media coverage for Lipum. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing an antibody drug for inflammatory diseases
lipum.seLast updated
In short: Lipum completed Flerie merger, published positive Phase I data, and secured €8 million Horizon Europe grant.
The company completed its merger with Flerie, published Phase I results, and secured €8 million in funding to prepare for proof-of-concept studies.
The results were published in RMD Open and show good safety, dose proportionality, and target binding.
The BEYOND project will advance the company's research and development of new therapies.
The grant from Horizon Europe funds the SOL-116 phase IIa study on rheumatoid arthritis in collaboration with partners.
The merger between investment firm Flerie and pharmaceutical company Lipum has now been finalized, according to a press release.Under the terms of the transaction, Lipum...
Redeye ceases its coverage of Lipum and will not provide research on the company following the completion of the merger between Flerie and Lipum and...
THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF...
A signed agreement with the European Commission would mean a significant capital injection without any dilution of ownership. Lipum leads a European consortium consisting of...
Track Lipum and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lipum and other trending companies.